![](/img/cover-not-exists.png)
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Goy, Andre, Forero, Andres, Wagner-Johnston, Nina, Christopher Ehmann, W., Tsai, Michaela, Hatake, Kiyohiko, Ananthakrishnan, Revathi, Volkert, Angela, Vandendries, Erik, Ogura, MichinoriLanguage:
english
Journal:
British Journal of Haematology
DOI:
10.1111/bjh.14094
Date:
April, 2016
File:
PDF, 301 KB
english, 2016